Galapagos NV Share Price Today: Live Updates & Key Insights

Galapagos NV share price today is $32.11, up -1.6%. The stock opened at $32.52 against the previous close of $32.53, with an intraday high of $32.53 and low of $31.782.

Galapagos NV Share Price Chart

Galapagos NV

us-stock
To Invest in {{usstockname}}
us-stock

Galapagos NV Share Price Performance

$32.11 -0.016(-1.6%) GLPG at 23 Mar 2026 01:20 PM Biotechnology
Lowest Today 31.782
Highest Today 32.53
Today’s Open 32.52
Prev. Close 32.53
52 Week High 37.78
52 Week Low 22.59
Day’s Range: Low 31.782 High 32.53
52-Week Range: Low 22.59 High 37.78
1 day return -
1 Week return -2.08
1 month return -5.51
3 month return -1.47
6 month return -5.51
1 year return +23.49
3 year return -14.66
5 year return -61.0
10 year return -

Galapagos NV Institutional Holdings

TANG CAPITAL MANAGEMENT LLC 6.30

Madison Avenue Partners, LP 3.33

EcoR1 Capital, LLC 2.53

Ameriprise Financial Inc 2.15

Prosight Management, LP 1.63

Columbia EAFE Value 1.06

Columbia Overseas Value Inst 1.06

Segall Bryant & Hamill 0.68

Point72 Asset Management, L.P. 0.67

Columbia EAFE Core 0.59

Columbia VP Overseas Core 3 0.55

Millennium Management LLC 0.52

Renaissance Technologies Corp 0.47

iShares Biotechnology ETF 0.43

D. E. Shaw & Co LP 0.42

BlackRock Inc 0.36

Hudson Bay Capital Management LP 0.26

UBS Group AG 0.23

Dafna Capital Management LLC 0.20

Cubist Systematic Strategies, LLC 0.16

Segall Bryant & Hamill Sm Cp Val Ins 0.14

Columbia Overseas Core Institutional 3 0.14

NORGES BANK 0.14

Citadel Advisors Llc 0.14

The Goldman Sachs Group Inc 0.10

Morgan Stanley - Brokerage Accounts 0.10

ALPS Medical Breakthroughs ETF 0.09

FMR Inc 0.09

VP Partners Small Cap Value 3 0.07

Pacific Select Large-Cap Growth I 0.07

Columbia Trust Overseas Value Founders 0.06

Barometer Global Equity Fund A 0.05

Vanguard US Opportunities Ins USD Acc 0.05

Schwab International Opportunities 0.05

Steward Values Enhanced International I 0.05

Avantis International Equity ETF 0.05

VALIC Company I International Value 0.04

ActivePassive International Equity ETF 0.02

ERSTE STOCK BIOTEC EUR R01 A 0.02

iShares Nasdaq US Biotech ETF USD Acc 0.02

Galapagos NV Market Status

Strong Buy: 0

Buy: 0

Hold: 4

Sell: 1

Strong Sell: 1

Galapagos NV Fundamentals

Market Cap 2256.67 M

PB Ratio 0.7543

PE Ratio 0.0

Enterprise Value -1368.19 M

Total Assets 3405.07 M

Volume 134842

Galapagos NV Company Financials

Annual Revenue FY25:1112200000 1112.2M, FY23:543968000 544.0M, FY22:505280000 505.3M, FY21:484846000 484.8M, FY20:478053000 478.1M

Annual Profit FY25:623100000 623.1M, FY23:526287000 526.3M, FY22:493201000 493.2M, FY21:483217000 483.2M, FY20:478053000 478.1M

Annual Net worth FY25:320900000 320.9M, FY23:-153069000 -153.1M, FY22:-217991000 -218.0M, FY21:-125422000 -125.4M, FY20:-311001000 -311.0M

Quarterly Revenue Q4/2025:900774000 900.8M, Q3/2025:71161000 71.2M, Q2/2025:65288000 65.3M, Q1/2025:74977000 75.0M, Q3/2024:59849000 59.8M

Quarterly Profit Q4/2025:440955000 441.0M, Q3/2025:60315000 60.3M, Q2/2025:60582000 60.6M, Q1/2025:61248000 61.2M, Q3/2024:59830000 59.8M

Quarterly Net worth Q4/2025:782162000 782.2M, Q3/2025:-202111000 -202.1M, Q2/2025:-105748000 -105.7M, Q1/2025:-153403000 -153.4M, Q3/2024:-50430000 -50.4M

About Galapagos NV & investment objective

Company Information Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Organisation Biotechnology

Employees 704

Industry Biotechnology

CEO Mr. Henry Gosebruch

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Galapagos NV FAQs

What is the share price of Galapagos NV today?

The current share price of Galapagos NV is $32.11.

Can I buy Galapagos NV shares in India?

Yes, Indian investors can buy Galapagos NV shares by opening an international trading and demat account with Motilal Oswal.

How to buy Galapagos NV shares in India?

You can easily invest in Galapagos NV shares from India by:

Can I buy fractional shares of Galapagos NV?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Galapagos NV?

Galapagos NV has a market cap of $2256.67 M.

In which sector does Galapagos NV belong?

Galapagos NV operates in the Biotechnology sector.

What documents are required to invest in Galapagos NV stocks?

To invest, you typically need:

What is the PE and PB ratio of Galapagos NV?

The PE ratio of Galapagos NV is N/A and the PB ratio is 0.75.